A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination with either JNJ-63723283 (cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

2022-503132-14-00 Protocol 78278343PCR1003 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 30 Jun 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol 78278343PCR1003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 205
Countries 1
Sites 4

Metastatic Prostate Cancer

Key facts

Sponsor
Janssen - Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
30 Jun 2025 → ongoing
Decision date (initial)
2025-03-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic Prostate Cancer

VersionLevelCodeTermSystem organ class
27.0 PT 10036909 Prostate cancer metastatic 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen - Cilag International

Sponsor organisation
Janssen - Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen - Cilag International
Contact name
CTIS Point of Contact

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 15 4
Rest of world
Australia, Korea, Republic of, United States
190

Investigational sites

Spain

4 sites · Ongoing, recruiting
Hospital Universitari Vall D Hebron
Oncology Service, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Oncology Service, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitario 12 De Octubre
Oncology Service, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Hm Sanchinarro
Oncology Service, Calle Ona 10, 28050, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2025-06-30 2025-06-30

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-26 Spain Acceptable
2025-03-06
2025-03-10
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-14 Spain Acceptable
2025-04-30
2025-05-20
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-04 Spain Acceptable
2025-10-15
2025-10-20